Altamira Therapeutics Ltd. (CYTOF) Net income 2018–2024
Altamira Therapeutics Ltd. (CYTOF) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$8.5MFY2024 · since FY2018: -$11.5M → -$8.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$8.5M | -96.4% |
| FY2023 | -$4.3M | +84.5% |
| FY2022 | -$27.8M | — |
| FY2020 | -$8.2M | -23.6% |
| FY2019 | -$6.6M | +42.3% |
| FY2018 | -$11.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CYTOF financial trends
CYTOF RevenueCYTOF Net marginCYTOF Gross profitCYTOF Gross marginCYTOF Operating incomeCYTOF Operating marginCYTOF Operating cash flowCYTOF Free cash flowCYTOF Capital expendituresCYTOF Return on equityCYTOF Stock buybacksCYTOF Dividends paidCYTOF Total assetsCYTOF Total liabilitiesCYTOF Shareholders’ equityCYTOF overview →